Inhibition of human cytomegalovirus protease N(o) with monocyclic beta-lactams.
Monocyclic beta-lactams have been identified as potent and selective inhibitors of the human cytomegalovirus protease (HCMV) N(o). Two series of these inhibitors are described, a peptidyl series of compounds and non-peptidic molecules featuring lower molecular weights. The SAR work that lead to the discovery of these inhibitors, together with their synthesis is also disclosed.
Déziel
R
R
Bio-Méga Research Division, Boehringer Ingelheim (Canada) Ltd, Laval, Québec, Canada.
Malenfant
E
E
D000900:Anti-Bacterial Agents / Q000737:chemistry / Q000494:pharmacology*; D006801:Humans; D008970:Molecular Weight; D011480:Protease Inhibitors / Q000737:chemistry / Q000494:pharmacology*; D012697:Serine Endopeptidases / Q000378:metabolism*; D013237:Stereoisomerism; D013329:Structure-Activity Relationship; D047090:beta-Lactams
D000900:Anti-Bacterial Agents; D011480:Protease Inhibitors; D047090:beta-Lactams; D012697:Serine Endopeptidases; C071910:assemblin